Vical researches and develops biopharmaceutical products based on its patented deoxyribonucleic acid (DNA) delivery technologies. Its DNA technologies are used for the prevention and treatment of serious or life-threatening diseases. The company has gained access to enhancing technologies through licensing and collaborative agreements. Vical researches vaccines for use in high-risk populations for infectious disease targets, vaccines for general pediatric or adult populations and cancer vaccines or immunotherapies for its existing programs. The company has retained all rights to its internally developed product candidates. Vical s manufacturing group has developed patented purification approaches that allow it to manufacture naked DNA plasmids in gram quantities within three to four months. Vical is based in San Diego and publicly traded on the NASDAQ under the symbol VICL.